Templeton’s [largest minority shareholder (c10% stake) in Taro] decision to switch sides and support Sun’s stance on the Taro impasse significantly boosts Sun’s chances of closing the Taro acquisition, in our view. While there are legal issues still pending in Israel & New York, with the largest minority shareholder on its side, Sun is likely to be able to go ahead even if a special tender offer is required.
Taro will help Sun Pharma gain scale & reach in the US market much faster than it would have been able to on its own – especially important given the disruption in its (more…)